ArticleCancer management and research2026
Peritoneal Metastasis in Advanced Lung Adenocarcinoma Harboring EGFR Exon 19 Deletion/T790M with STRN::ALK Fusion and EGFR Kinase Domain Duplication: Two Case Reports and a Narrative Literature Summary.
Article in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peritoneal metastasis from lung adenocarcinoma is rare and generally associated with poor prognosis. Here, we report two cases of advanced NSCLC with multiple metastases in which the patients developed rare peritoneal metastases during disease progression. Next-generation sequencing (NGS) revealed rare genomic alterations: one patient harbored concurrent EGFR exon 19 deletion and T790M mutation, accompanied by EGFR amplification, TP53 mutation, and STRN::ALK fusion, while the other exhibited EGFR kinase domain duplication and TP53 mutation. Both patients underwent multiple lines of systemic therapy, including targeted treatment guided by NGS results, and achieved survival exceeding six months following the diagnosis of peritoneal metastasis, with ongoing treatment at last follow-up. These observations suggest that more precise molecularly guided targeted therapy may play a crucial role in the clinical management of peritoneal metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.